Singapore markets close in 39 minutes
Straits Times Index
3,267.79 +42.62 (+1.32%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,823.04 +311.35 (+1.89%) FTSE 100
8,053.32 +29.45 (+0.37%) Bitcoin USD
66,101.25 -26.41 (-0.04%) CMC Crypto 200
1,393.72 -21.04 (-1.49%)
UroGen Pharma Ltd. (0XOD.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 05:14PM BST. Market open.
| Previous close | 14.14 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 457 |
| Market cap | 1.889M |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Simply Wall St.
UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the...
- Simply Wall St.
UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
UroGen Pharma ( NASDAQ:URGN ) Full Year 2023 Results Key Financial Results Revenue: US$82.7m (up 28% from FY 2022). Net...
© 2024 Yahoo. All rights reserved.